Back to search results

Comparing Pain Relief After Nose Surgery

This study is comparing two pain medications, Liposomal Bupivacaine and Standard Bupivacaine, to see which is better at reducing pain after nose surgery (rhinoplasty). Both medications are given as nerve blocks, which means they are injected near nerves to block pain signals. The goal is to find the best treatment to reduce discomfort and improve healing. You may be able to join if you are an adult (18 or older) having open rhinoplasty for any reason. We will measure how much opioid pain medication you use in the first 72 hours after surgery to see which treatment is more effective. The current status of this study is unclear.

Study design
This interventional study plans to enroll 45 participants. You would be randomly assigned to receive either Liposomal Bupivacaine or Standard Bupivacaine.
What's involved
After surgery, you will be asked to rate your pain levels over several days. The investigators will also monitor any side effects and how quickly you recover.
Compensation
Not stated in the trial record.
Follow-up
Your opioid consumption will be measured for the first 72 hours postoperatively.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07689162

Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Washington University School of Medicine
~45 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:Standard BupivacaineLiposomal Bupivacaine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cumulative opioid consumption
Measured over First 72 hours postoperatively

Conditions

Pain, Postoperative

Explore related trials

Rhinoplasty

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Matthew Wu, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Matthew Wu, MD
[email protected]
314-362-0524
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients (≥18 years) undergoing open rhinoplasty of any indication or complexity (e.g., primary, revision, functional, or cosmetic), including autologous grafting of any type (e.g., septal or costal cartilage) or cadaveric grafting.

Exclusion

Chronic pain condition requiring ongoing or scheduled analgesic therapy, or any diagnosis associated with chronic pain (e.g., fibromyalgia, chronic headache/migraine, neuropathic pain, complex regional pain syndrome), long-term opioid use (≥3 months, any agent), allergy or contraindication to local anesthetics, acetaminophen, ibuprofen / NSAIDs, tramadol, ketamine, Medrol (methylprednisolone) dose pack
Concurrent non-nasal surgery planned

What this trial measures

  • Cumulative opioid consumptionFirst 72 hours postoperatively

    Cumulative opioid consumption in the first 72 post-operative hours expressed in morphine milligram equivalents (MME).